SCIENTIFIC BACKGROUND

CACNA1S, KCNJ2, SCN4A

Category:

Scientific Background

Autosomal dominant inherited primary periodic paralyses are characterized by reversible episodic muscle weakness and intermittent myotonia. Seizure-like paralyses regress within a few hours to a few days; respiratory muscles are less affected, and consciousness and speech are always unaffected. It is caused by dysfunction in the muscular ion channels (sodium, calcium, potassium channels) that control myocyte activity. Muscle weakness may be associated with changes in serum potassium levels, and it can be differentiated into hyperkalemic or hypokalemic periodic paralysis. However, a clinical differentiation based on serum potassium, which must be determined during the onset of symptoms, is not always possible.

 

The most common form is hypokalemic periodic paralysis (HypoPP), which has a prevalence of 1:100,000. The paralysis of all extremities, which lasts from one hour to days, is accompanied by a drop in serum potassium level below 3mmol/L (reference value: 3.5-5mmol/L). The severity of the paralysis can be highly variable: from mild weakness to complete paralysis of the extremities. The first symptoms usually appear before the age of 20, with a peak in seizure frequency between the ages of 15 and 35. The seizures can be triggered by factors including high-carbohydrate meals, stress, alcohol consumption, or physical exertion. In very severe cases, persistent weakness of the limb-girdle muscles may develop later during the course of the disease.

 

Pathogenic variants in the CACNA1S gene can be detected in approximately 60% of patients with HypoPP. This gene encodes the alpha-1 subunit of the muscular voltage-gated calcium channel CaV1.1 that is predominantly expressed in skeletal muscle and the retina. Variants in this gene are also associated with a predisposition to malignant hyperthermia. Pathogenic variants in the SCN4A gene are found in approximately 10% of HypoPP cases.

 

References

Fialho et al. 2018, Handb Clin Neurol 148:505 / Statland et al. 2018 Muscle Nerve 57:522 / Statland et al. 2013, Continuum (Minneap Minn) 19 (6 Muscle Disease):1598 / Matthews et al. 2010, J Physiol 588:1879 / Striessnig et al. 2010, Pflugers Arch 460:361 / Rayan & Hanna 2010, Curr Op in Neur 23:466

GENES

CACNA1S, KCNJ2, SCN4A

ASSOCIATED TESTS

How to order

LATEST ARTICLES

A new meta-analysis links trans-kingdom gut microbiota (bacteria, eukaryotes, viruses, archaea) to immune checkpoint inhibitor (ICI) response in canc...

Read more

Reproductive health is a fundamental aspect of human well-being, affecting individuals and communities worldwide [1]. It encompasses a wide range of ...

Read more

It seems as though everyone is talking about artificial intelligence, usually referred to as AI, these days! Indeed, not only are AI tools now access...

Read more

Orphan drugs are those developed specifically for the treatment of rare diseases. Within the pharmaceutical industry, the drug development process is...

Read more

A study of 629 pregnancies with ultrasound-detected anomalies found that exome sequencing identified pathogenic variants in 14% of cases. The detecti...

Read more

Breast cancer is a type of cancer that originates in the breast cells. Genetic changes in the DNA of the healthy breast cells can lead to the formati...

Read more

Cardiovascular diseases affect the heart and blood vessels and are a leading cause of illness and death. Some are hereditary, and genetic testing can...

Read more

A recent study tracked molecular changes in 108 people over time, revealing that aging involves critical shifts around ages 44 and 60. These changes ...

Read more

In May 2024, the American Society of Clinical Oncology (ASCO) published new guidelines for germline genetic testing in patients with cancer (1). ...

Read more

Genetics as we know and understand it today has been shaped, over decades, by the work of many dedicated scientists around the world, and they all de...

Read more